TPI Composites files for Chapter 11 bankruptcy, plans delisting from Nasdaq
Dianne C. Whitfield, the Chief Human Resources Officer at Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), a $1.9 billion market cap company whose stock has surged 44% in the past six months, recently executed a series of stock sales totaling $321,323. These transactions, filed with the Securities and Exchange Commission, occurred over three days from March 18 to March 20. The shares were sold at prices ranging from $46.29 to $50.11, near the current trading price of $49.91.
The sales involved 2,315 shares on March 18, 2,259 shares on March 19, and 2,137 shares on March 20. These transactions were made to cover tax withholding obligations related to the vesting and settlement of Restricted Stock Units, as mandated by the company’s policy. Following these sales, Whitfield retains ownership of 46,355 shares in the company. According to InvestingPro data, TARS maintains strong financial health with more cash than debt and a robust current ratio of 4.42, while analysts maintain a bullish outlook on the stock. Discover comprehensive insider trading patterns and 8 additional key insights with InvestingPro’s detailed analysis.
In other recent news, Tarsus Pharmaceuticals completed a substantial stock offering, securing approximately $134.8 million in net proceeds. The offering included the sale of over 3.2 million shares, with underwriters led by Goldman Sachs, BofA Securities, and Barclays (LON:BARC) fully exercising their option to purchase additional shares. This capital raise is expected to support Tarsus Pharmaceuticals’ operations and research endeavors. Furthermore, the company launched another public offering of $100 million in common stock, with a 30-day option for underwriters to purchase additional shares. Analysts have shown confidence in Tarsus Pharmaceuticals, with Jefferies raising the stock target to $58 and maintaining a Buy rating, citing notable financial performance and a promising outlook for revenue growth. Guggenheim also increased its price target to $78, following strong sales of Xdemvy, which exceeded expectations. Meanwhile, H.C. Wainwright reaffirmed a Buy rating and a $73 price target, addressing investor concerns and expressing confidence in the company’s growth prospects. These developments highlight Tarsus Pharmaceuticals’ recent activities and the positive reception from analysts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.